MOUNJARO 12.5MG PEN (Tirzepatide 12.5 mg)

Composition
Each prefilled pen contains Tirzepatide 12.5 mg as a sterile solution for subcutaneous injection.

Description
MOUNJARO 12.5 mg Pen is a long-acting antidiabetic injectable medication indicated for the treatment of type 2 diabetes mellitus. Tirzepatide is a dual GIP and GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon release, delays gastric emptying and reduces appetite. These combined actions help achieve effective glycaemic control and support weight reduction when used along with proper diet and lifestyle measures.

Adverse Effects
The most commonly reported adverse effects include nausea, vomiting, diarrhoea, constipation, abdominal discomfort and decreased appetite, particularly during dose escalation. Injection site reactions such as pain, redness or swelling may occur. Hypoglycaemia can occur when used concomitantly with insulin or insulin secretagogues.

Precautions
MOUNJARO should be administered only by subcutaneous injection and should not be given intravenously or intramuscularly. Caution is advised in patients with a history of pancreatitis, severe gastrointestinal disorders or thyroid disease. Gradual dose escalation is recommended to minimize gastrointestinal side effects. Use during pregnancy or lactation should be undertaken only on medical advice. Regular monitoring of blood glucose levels is advised during treatment.

Storage
Store under refrigeration at 2°C to 8°C and protect from light. Do not freeze. After first use, store as per manufacturer’s recommendations. Keep out of reach of children.